Device M&A Rebound Continues: With Ardian, Sadra Deals Show Appetite For Big, Early-Stage Acquisitions

The year looks to be closing strong in terms of device M&A as the rebound we noted last month has continued, highlighted by the recent acquisitions of Ardian, with its novel percutaneous technology for hypertension (and perhaps other conditions), by Medtronic in what could turn out to be a billion dollar deal, and Boston Scientific's leap into the hot transcatheter valve space with its acquisition of Sadra Medical. At a time when acquirers and investors claim to be looking primarily for more mature, commercial-stage companies, these deals indicate that there remains a robust demand for truly innovative devices that address significant unmet needs and markets

The year looks to be closing strong in terms of device M&A as the rebound we noted last month has continued, highlighted by the recent acquisitions of Ardian Inc., with its novel percutaneous technology for hypertension (and perhaps other conditions), by Medtronic PLC in what could turn out to be a billion dollar deal, and Boston Scientific Corp.'s leap into the hot transcatheter valve space with its acquisition of Sadra Medical Inc.[See Deal][See Deal] These deals also demonstrate that, at a time when acquirers and investors claim to be looking primarily for more mature, commercial-stage companies, and when questions are arising about the innovation model shifting to focus on "good enough" products, there remains a robust demand for truly innovative devices that address significant unmet needs and markets. ( See "In Medical Devices, Is "Good Enough" Good Enough?" this issue Also see "In Medical Devices, Is "Good Enough" Good Enough? " - In Vivo, 1 December, 2010..) Neither Ardian nor Sadra is close to commercializing products in the US and significant risks remain for both companies, yet Medtronic and Boston Scientific both paid handsome premiums to expand their existing businesses into these promising emerging areas.

The acquisitions add to what already has been an improved year for medical device mergers and acquisitions. ( See "Stryker...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.